Literature DB >> 22226109

Autologous stem cell transplantation and multiple myeloma cancer stem cells.

William Matsui1, Ivan Borrello, Constantine Mitsiades.   

Abstract

It is well established that high-dose therapy (HDT) combined with autologous stem cell transplantation (ASCT) produces superior response rates and progression-free survival compared with conventional chemotherapy in patients with multiple myeloma (MM). Accordingly, MM currently represents the most common indication for ASCT. Despite these clinical improvements, the impact of ASCT on overall survival is unclear because the vast majority of patients eventually experience disease relapse and progression. The continual risk of relapse suggests that malignant cells resistant to HDT possess the clonogenic growth potential to mediate tumor regrowth, and in several diseases cancer stem cells (CSCs) have been identified that are both highly tumorigenic and resistant to standard anticancer approaches. Putative CSCs have been identified in MM, and their characterization may lead to the development of novel maintenance strategies that inhibit the production of new tumor cells, prevent disease relapse, and improve overall survival.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22226109      PMCID： PMC3260462          DOI： 10.1016/j.bbmt.2011.10.036

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


  43 in total

1.  Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).

Authors:  B Björkstrand; H Svensson; H Goldschmidt; P Ljungman; J Apperley; F Mandelli; R Marcus; M Boogaerts; A Alegre; K Remes; J J Cornelissen; J Bladé; S Lenhoff; A Iriondo; K Carlson; L Volin; T Littlewood; A H Goldstone; J San Miguel; A Schattenberg; G Gahrton
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

2.  Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice.

Authors:  L M Pilarski; G Hipperson; K Seeberger; E Pruski; R W Coupland; A R Belch
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

3.  Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma.

Authors:  T Rasmussen; L Jensen; L Honoré; H E Johnsen
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

4.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

5.  A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.

Authors:  D Cunningham; R Powles; J Malpas; N Raje; S Milan; C Viner; A Montes; T Hickish; M Nicolson; P Johnson; J Treleaven; J Raymond; M Gore
Journal:  Br J Haematol       Date:  1998-07       Impact factor: 6.998

6.  Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell.

Authors:  M H Bakkus; I Van Riet; B Van Camp; K Thielemans
Journal:  Br J Haematol       Date:  1994-05       Impact factor: 6.998

7.  Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.

Authors:  S Yaccoby; B Barlogie; J Epstein
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

8.  In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.

Authors:  P L Bergsagel; A M Smith; A Szczepek; M J Mant; A R Belch; L M Pilarski
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

9.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.

Authors:  M A Goodell; K Brose; G Paradis; A S Conner; R C Mulligan
Journal:  J Exp Med       Date:  1996-04-01       Impact factor: 14.307

10.  The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cell.

Authors:  D Billadeau; G Ahmann; P Greipp; B Van Ness
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307
View more
  10 in total

1.  Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Authors:  M Gkotzamanidou; E Terpos; C Bamia; S A Kyrtopoulos; P P Sfikakis; M A Dimopoulos; V L Souliotis
Journal:  Leukemia       Date:  2013-10-03       Impact factor: 11.528

2.  CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.

Authors:  Sara Yousef; Magdalena Kovacsovics-Bankowski; Mohamed E Salama; Neelam Bhardwaj; Mary Steinbach; Amanda Langemo; Tibor Kovacsovics; James Marvin; Mascha Binder; Jens Panse; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 4.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

Review 5.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Gastric cancer stem cells in gastric carcinogenesis, progression, prevention and treatment.

Authors:  Kang Li; Zeng Dan; Yu-Qiang Nie
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742

8.  The systemic cytokine environment is permanently altered in multiple myeloma.

Authors:  Mary M Zheng; Zhifang Zhang; Kyle Bemis; Andrew R Belch; Linda M Pilarski; John E Shively; Julia Kirshner
Journal:  PLoS One       Date:  2013-03-27       Impact factor: 3.240

9.  Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.

Authors:  Sara Yousef; Johanna Heise; Nesrine Lajmi; Katrin Bartels; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  J Transl Med       Date:  2015-06-20       Impact factor: 5.531

10.  Identification of the xenograft and its ascendant sphere-forming cell line as belonging to EBV-induced lymphoma, and characterization of the status of sphere-forming cells.

Authors:  Evgeniya V Dolgova; Daria D Petrova; Anastasia S Proskurina; Genrikh S Ritter; Polina E Kisaretova; Ekaterina A Potter; Yaroslav R Efremov; Sergey I Bayborodin; Tatiana V Karamysheva; Margarita V Romanenko; Sergey V Netesov; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Sergey S Bogachev
Journal:  Cancer Cell Int       Date:  2019-05-06       Impact factor: 5.722
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.